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Introduction
Evidence, including the recent findings of  the START study, 
shows the overwhelming success of  early HIV treatment in 
lowering the risk of  developing AIDS as well as preventing 
HIV transmission.2 Access to antiretroviral therapy (ART) has 
improved significantly in recent years. At the end of  2013, there 
were 12.9 million people receiving ART, with 5.6 million of  
those added since 2010.3 Nonetheless, at the end of  2013 only 
37% of  people living with HIV were receiving treatment, leaving 
22 million people in need of  ART.4 In 2014, UNAIDS set the 
90-90-90 target – an “ambitious but achievable” goal toward 
ending the AIDS epidemic by 2030 (see Box 1).
The 90-90-90 target focuses on equity; UNAIDS notes “it will 
be impossible to end the epidemic without bringing HIV treat-
ment to all who need it.”5 This brief  demonstrates how gender 
dynamics impact HIV treatment access and adherence and illus-
trates how greater attention to these dynamics within HIV inter-
ventions can improve treatment uptake and adherence critical to 
achieving the 90-90-90 goal. This brief  uses WHO’s HIV care 
cascade as a useful framework within which to view the evidence 
regarding how gender dynamics help or hinder HIV treatment 
efforts (see Figure 1). This brief  also identifies priority actions 
needed for gender-equitable treatment programming to achieve 
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About this brief
This brief provides policymakers and program implementers 
with evidence about the impact of gender dynamics on 
treatment access and adherence and the gender-related 
gaps in treatment research and programming. It also 
includes priority actions that can be taken to better address 
gender within treatment programming and raises questions 
for implementation science in order to achieve the global 
90-90-90 goals (see Box 1). This brief draws from What 
Works For Women and Girls: Evidence for HIV Interventions 
(www.whatworksforwomen.org) and uses the WHO treatment 
cascade framework to identify and analyze major gender 
considerations in providing antiretroviral therapy to those 
living with HIV in low- and middle-income countries. It 
focuses on antiretroviral treatment access and adherence as 
well as the gender dynamics related to who gets tested and 
under which circumstances. The brief does not cover the full 
provision of “HIV care” defined in the cascade to also include 
prevention, detection and treatment of co-infections such 
as TB, as well as nutrition and social support.1 For more on 
gender dynamics within those topics and to read about the 
full methodology for the evidence review, please see www.
whatworksforwomen.org. 
the 90-90-90 goal. Given that there are few evaluated gender 
interventions for HIV treatment, these priority actions, 
along with additional questions for implementation science, 
are based on programmatic and technical expertise, as well 
as a review of  the literature. The actions can be carried out 
at multiple levels such as at the community, clinic and policy 
levels and, though far from a comprehensive list, illus-
trate how a gender lens can be useful in ensuring equity in 
treatment access and adherence. Further dialogue, research, 
programming, and importantly – evaluation – is needed with 
input from multiple stakeholders.
Gender Dynamics within the 
Care Cascade
Knowing One’s HIV Status
There are often gender differences in who gets tested and 
why. A review of  the literature on studies conducted in rural 
India from 1980 to 2008 found that men sought testing 
because they were personally concerned, whereas women 
sought testing upon the recommendation of  their antenatal 
provider - and in some cases reported mandatory testing 
by their provider.6 Most women access HIV testing within 
maternal health services. Since they come into contact with 
the health system regularly, pregnant women are dispropor-
tionately tested for HIV.7 A 2009 study in rural Mozam-
bique found that HIV testing in non-pregnant women was 
“uncommon.”8 The emphasis on counseling and testing 
for prevention of  maternal to child transmission (PMTCT) 
means that women who are not pregnant are inadequately 
reached with HIV testing and counseling services.
Women must navigate a number of  hurdles in accessing 
testing. Many women, especially rural women, are unable 
to afford the time or money required to travel to a facility 
providing HIV testing. In some places, high rates of  
illiteracy mean that many women cannot access written 
information about the benefits or availability of  HIV testing. 
Stigma, gender inequalities, and fear of  negative outcomes 
following disclosure are significant barriers. Such outcomes 
include moral judgment and blame; ostracism by household 
or community; relationship termination; verbal and/or 
physical abuse as well as discrimination. In many countries, 
women living with HIV are spoken of  as being promiscuous 
women who deserve this disease as a punishment for their 
sins.9 Fear of  stigma and discrimination from health care 
providers is also a concern, especially for women from 
marginalized groups such as those who are sex workers or 
transgender.
Gender Norms Affect Men As Well as Women
Men, too, must overcome barriers to testing. A study 
in Lesotho found that there was better access to testing 
for women and a strong fear of  testing among men.10 
Global attention has focused often on prevention of  
vertical transmission,11 putting men simply in the role of  
supporting access to services for their female partners 
living with HIV, rather than caring for their own needs. In 
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Box 1
90-90-90 Target
By 2020:
• 90% of all people living with HIV will know their 
HIV status.
• 90% of all people with diagnosed HIV infection 
will receive sustained antiretroviral therapy.
• 90% of all people receiving antiretroviral therapy 
will have viral suppression.
Source: UNAIDS, 2014
Figure 1
HIV Care Cascade
Focus of this brief
Source: WHO, 2015
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many areas of  the world, HIV is seen as a threat to a man’s 
masculinity, “requiring him to seek care, challenging his 
notions of  fearlessness, and fueling fears of  humiliation 
and that his wife will desert him.”12 Men also may worry 
that they acquired HIV from extramarital partnerships and 
may therefore be less likely to disclose their HIV-positive 
serostatus to their spouse13 or to want to get tested in the 
first place. 
A study in South Africa—where counseling and testing for 
HIV is most frequently accessed in antenatal care settings 
and a few stand-alone centers14 —found that men rarely 
initiate discussions with their female partners concerning 
HIV testing and mostly relied on female partners to test 
as a means of  determining their own HIV status, not 
understanding that sexual partners who are serodiscordant 
can exist.15 Focus group discussions with young men 
in Malawi and Uganda found that gender norms, such 
as equating masculinity with invulnerability and sexual 
conquest, were the reasons they would not access HIV 
testing and counseling.16 
Addressing gender norms that suggest that ‘real men do 
not get sick’ will be critical to increasing HIV testing and 
counseling by men, as well as creating more opportunities 
for men to get HIV testing and counseling.17 Rapid 
expansion of  testing, however, without ensuring informed 
consent and confidentiality could increase the risk of  
women and transgender people being rejected by their 
families, losing their property, and suffering violence and 
abuse. As noted by Jürgens and Cohen, “efforts to increase 
access to HIV testing must be accompanied by vastly 
scaled up efforts to confront the stigma and human rights 
abuses that deter people from seeking HIV tests in the first 
place….”18
Priority Actions for Programming and Policy
 ■ Expand coverage to reach more women 
 — Expand coverage of  HIV testing and counsel-
ing both within and outside of  antenatal care 
settings.
 ■ Link ART services with gender-based violence 
services
 — Strengthen referral programs for testing and 
ART services with services for gender-based 
violence.
 ■ Reach men
 — Promote campaigns that counter the harmful 
gender norm that “real men don’t get sick”; 
promote positive images of  men using health 
services for the benefit of  themselves, their part-
ners, and their families.
 ■ Create programs to reach men as independent 
users of  health services rather than exclusively 
through their female partners, both for testing 
and for treatment
 — Create testing programs for male clients of  sex 
workers with linkage to treatment.
 ■ Strengthen couples testing
 — Revise national and local guidelines to include 
a context-appropriate definition of  a “couple,” 
gender-sensitive ways to engage men and women 
in counseling, and linkages to available gen-
der-based violence services, when needed. 
 ■ Reach youth
 — Create opportunities for testing with linkage to 
treatment services in schools and universities in 
order to reach young men and young women 
prior to their first pregnancy.
Questions for Implementation Science
 ■ How can the number of  men as users of  health 
services – particularly for testing and treatment – be 
increased?
 ■ How can stigma be reduced to encourage greater 
uptake of  HIV testing? 
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Box 2
Why is sex- and age-disaggregated data 
important?
Because it helps identify gaps in treatment 
programming. 
For example, of 10,000 people on treatment in 
Malawi (Makwiza et al., 2008):
• More men than women accessed treatment in 
the 15-19 year age group, yet HIV prevalence in 
this age group was higher among women.
• More women than men accessed treatment in 
the 30-39 year age group, yet HIV prevalence 
was higher among men in this age group.
Without sex- and age-disaggregated data, these 
inequities are masked under one number: “10,000 
on treatment” and critical programming gaps would 
remain unnoticed.
Gender Considerations Along the HIV Treatment Cascade: An Evidence Review with Priority Actions
Enrollment in ART & Treatment Care*
Gender norms affect treatment access for men and 
women. Women constitute a higher proportion of  those 
receiving ART than men. For all low- and middle-income 
countries, women constitute 51% of  those eligible for care 
but make up 59% of  those receiving ART.19 However, 
while more women than men have accessed treatment 
globally, structural factors and traditional gender norms can 
jeopardize women’s adherence, retention in care or ability to 
reduce transmission.
“Women are often more likely than men to attend health 
services because of  dedicated provision of  reproductive 
and child health clinics.”20 Many women are first tested 
and then put on treatment with the goal of  prevention of  
vertical transmission. But inadequate attention is given to 
the treatment needs of  women outside of  this scope. The 
new WHO guideline recommending Option B+ allows 
pregnant women living with HIV to remain on treatment 
for life following their pregnancy. But the word “option” is 
a misnomer – it is an option for the country, not necessarily 
for the pregnant women. In a study in Malawi and Uganda, 
pregnant women were told they could have less than 24 
hours to consider whether to go on treatment for life – a 
weighty decision. As one woman put it: “I’m 18 years, you 
are telling me drugs for life?”21 In addition, the focus has been 
on prevention of  vertical transmission, or as one woman 
living with HIV states: “The doctors say, ‘Listen, we are not giving 
you these ARVs to save you, we are saving the baby….’’”22 It is 
not surprising, therefore, that there are high dropout rates 
from treatment programs postpartum, including Option 
B+.23 In several countries, Option B+ rollout “has been 
characterized by high levels of  ‘loss to follow up’ and lower 
rates of  adherence.”24 
In addition, male involvement in Option B+ has been 
* Note that this brief  focuses on antiretroviral therapy and does not fully 
cover all aspects of  treatment care such as treating co-infections and 
provision of  nutritional and social support.
interpreted in some countries as a requirement that a man 
be present to access treatment. Some women instead choose 
to hire men to pose as their male partners: “Because when 
you go to antenatal you are asked to come with your partner, 
women have chosen to hire boda boda (motorcycle taxi 
drivers) to go with them to access the services.”25 Priority 
for treatment access to pregnant women creates problems 
within relationships: “Actually, the first time I was told about 
Option B+, the first question I remember I asked was ‘what about 
the man?’ Why did I ask this? Because I really saw that there were 
going to be conflicts of  interest because men are going to now say, ‘Why 
women? Aren’t we also human beings?’” Or as another woman 
put it: “Men will say, ‘It’s me who made that woman pregnant. Why 
am I not started on treatment too?’”26
Men Often Enroll in ART Later than Women
The Institute of  Medicine notes that for PEPFAR data, 
each year there were more initial enrollments in ART among 
women than among men; the proportion has remained 
steady over time at about 65% of  women and 35% of  
men. This imbalance is greater than the difference in HIV 
prevalence between men and women.27 Patient data from 
307,110 adults from Kenya, Mozambique, Rwanda and 
Tanzania between 2006 and 2011 found that risk of  late 
enrollment (CD4 counts under 350) was significantly higher 
for men and nonpregnant women as compared to pregnant 
women.28
Harmful gender norms (e.g., viewing seeking health care as 
weakness) frequently cause men to delay presentation for 
treatment, which can reduce their life expectancy. A study 
of  4,775 patients from Uganda found there was a higher 
death rate for men, even when the analysis included women 
who accessed ART outside of  ANC services, with more 
men presenting for care with lower CD4 counts, with single 
men having significantly lower CD4 counts than married 
men or single women.29
“…Although women remain more vulnerable to HIV 
infection, once infected, men tend to be disadvantaged in 
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terms of  access to treatment and care.” In many countries, 
men initiate treatment later, are more likely to be lost to 
follow up, and have higher mortality rates.30 Focus group 
discussions with men in Uganda found that men found it 
difficult to seek treatment, which contradicted their assumed 
masculine autonomy and superiority.31
A global review based on 36 studies in resource-rich and 
resource-limited settings found that being a heterosexual 
male was a consistent risk factor for presenting with low 
CD4 counts, resulting in less favorable outcomes for men 
once enrolled in treatment.32 In South Africa in 2011, the 
fraction of  ART-eligible women who were receiving ART 
(65%) was significantly higher than the fraction of  ART-
eligible men who were on treatment (41%).33 An analysis 
of  23 cohort studies from Africa, including 216,008 
participants found that only 35% of  those accessing 
ART were men, despite an HIV prevalence of  40%, 
representing “a significant underrepresentation of  men in 
ART programs.”34 In addition, the risk of  death for men 
was 1.37 times higher than for women.35 However, men are 
seldom targeted as they are not often classified as vulnerable 
or marginalized.36 While this inequitable access for men to 
ART may be due, in part, to a focus on maternal health, 
equitable access to ART for men “should be conducted 
without …threatening HIV…treatment for women.”37 
A study of  sex differentials in ART uptake in Zambia found 
that men were more likely to refuse ART even though men’s 
self-rated health was lower than women’s, with norms of  
masculinity presenting the biggest barrier for male uptake 
of  ART.38 Other studies have found that men who received 
treatment39 were more likely to die than women because 
of  late presentation for treatment or were frequently lost 
to follow up.40 A study of  programmatic data on 334,557 
adults enrolling in HIV care at 132 facilities in Kenya, 
Mozambique, Rwanda and Tanzania found that men were 
1.6 times more likely to initiate ART with advanced HIV 
disease (CD4 count under 100) compared with women and 
that “this disparity seems to be widening….”41 A recent 
study found that men used their economic and decision-
making power to informally access ART in order not 
to be seen at clinics, which are seen as a woman’s space. 
Out of  shame, men suffered silently and attempted to 
cope by stealing their wives’ ARVs. The practice of  men 
stealing ARVs from their wives endangers both partners, 
jeopardizing women’s adherence.42
Gender norms of  female submissiveness and women as 
caretakers may be critical also for the higher uptake of  
ARVs by women, as explained by one Vietnamese woman 
living with HIV: “Women have no choice but to take the drugs. 
Meanwhile, men are the ones who consider whether or not to take 
the drugs because they don’t need to think of  anything else except 
themselves.”43 Greater attention needs to be paid to ensuring 
that men living with HIV know their serostatus, have 
access to condoms, understand the need for consistent and 
correct condom use, and have equitable access to treatment. 
“Closing the coverage gap in men needs to be a priority to 
tackle health-related gender inequalities, improve overall 
health in men, and decrease transmission….”44
Inequitable Access to ART Also Differs by Age and 
Social Status
Some studies have found that equity in access differs by 
age group with inadequate treatment access for adolescent 
women. In Malawi, for example, of  10,000 people on 
treatment, proportionately more women accessed treatment 
than men. However, in the 15 to 19 year age group, more 
men were proportionately on treatment despite the fact 
that HIV prevalence in this age group was higher among 
women.45 “Despite the growing number of  older children 
and adolescents who develop symptoms, there has been 
little focus on providing this group with specialized HIV 
care.”46 Providers need training to provide nonjudgmental 
care. Instead, one study found that providers would say to 
adolescents living with HIV: “You are HIV-positive. You are not 
expected to have sex. You are not expected to have a baby.”47
Transgender people are marginalized and subject to 
stigma, violence and social exclusion,48 which can affect 
treatment access and adherence. Similarly, sex workers 
– who are, worldwide, mostly women49 and among the 
most marginalized of  women50 – face barriers in accessing 
treatment due to stigma, discrimination and social 
exclusion.† Importantly, WHO notes that key populations 
should have the same access to ART and care and the 
same ART management as other populations, “[h]owever, 
because of  stigma, discrimination and marginalization, 
they frequently present late for treatment.”51 Thus, ART 
programming that respects human rights is critical - for key 
populations, as for all.
Priority Actions for Programming and Policy
 ■ Strengthen services
 — Ensure that all service providers are trained in 
the principles of  non-discrimination to ensure 
that people of  different gender identities can 
access quality services with respectful treatment, 
counseling and support. 
† While transgender issues are raised throughout this brief, a full dis-
cussion of  the barriers to treatment by sex workers, people who use 
drugs and other key populations is beyond the scope of  this brief. 
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6 — Identify avenues to provide treatment to women 
outside of  antenatal care services to reach wom-
en who are not pregnant.
 ■ Reach men
 — Create both an inclusive atmosphere as well as 
physical space within clinics where men can initi-
ate ART with follow up within communities and 
with male peer support.
 ■ Reach youth
 — Create services that will reach adolescent girls 
living with HIV, particularly those under age 18 
who will not be reached through pediatric ser-
vices yet are not comfortable in adult settings.
 — Create sustainable adolescent friendly HIV ser-
vices that also meet reproductive health needs.
 ■ Review data
 — Analyze HMIS data on an ongoing basis to assess 
gender equitable access, adherence, and retention 
to ensure that care and treatment services are 
reaching people in proportion to the burden of  
the epidemic.
Questions for Implementation Science
 ■ How can men’s engagement with health and ART 
services be fostered without interfering with 
women’s decision-making and autonomy?
 ■ How can treatment programming reach those who 
have not yet been reached?
ART Retention
For the most part, men and women have similar ART 
adherence rates. But there are gender differences in 
predictors of  adherence. Women may need family support, 
including redistribution of  household responsibilities, to 
enable them to adhere to treatment. Even if  drugs are free 
or subsidized, women may not be able to afford the time 
or money required to travel to a clinic. A qualitative study 
of  women living with HIV in Colombia found that women 
prioritized the needs of  their HIV-positive children over 
their own adherence needs.52 Women in Malawi and Uganda 
also reported financial and other challenges in managing 
their own adherence as well as that of  their children.53 
Some women sold their ARVs for economic survival.54 
Women may also have difficulty navigating treatment when 
it conflicts with other activities for survival. Sex workers, in 
particular, face difficulties in adherence in large part due to 
stigma and discrimination. One South African sex worker 
points out the struggles she faces: “If  you don’t pay off  the 
police, they take you to jail…you can’t take antiretroviral drugs or 
any medication you need.”55 Female sex workers in Vietnam 
reported that they were not allowed to join networks of  
people living with HIV who gained access to valuable 
support and information services because they were seen as 
“social evils” rather than “innocent wives getting the disease 
from their husband.”56
Other Life Activities Affect Women’s Adherence
Pregnancy represents an additional sex-related factor in 
treatment. In a study of  4,531 women from numerous 
treatment sites in Sub-Saharan Africa, one-third experienced 
a pregnancy within four years of  ART initiation.57 Yet few 
treatment programs are designed with the likelihood of  
pregnancy in mind.58 Most of  the world’s women living 
with HIV are of  reproductive age and will need either 
contraception or discussions on how to become pregnant 
while reducing the risk of  HIV transmission to their infants 
and/or partners.
Side effects can also deter women from adhering to 
treatment plans. Some medications cause a redistribution 
of  body fat resulting, for example, in a large belly, or a 
collection of  fat at the base of  the neck, or loss of  fat 
from the cheeks.59 Women have reported problems with 
adherence due to how ARVs changed their appearance, 
with bodily changes creating visibility of  their HIV-positive 
serostatus and consequent stigma. Women may also be more 
adversely affected by the common side effects of  ARVs that 
result in anemia.60 A study of  quality of  life among people 
living with HIV in Cuba found that pain interfered more in 
women’s lives than in men’s lives, and that women did not 
enjoy the same health-related quality of  life as men.61 In 
Vietnam, men, even if  they injected drugs, reported better 
quality of  life on antiretroviral therapy than did women, as 
women cared for the men.62 
Men’s Sense of Masculinity Can Affect Treatment 
Adherence
Men also face particular challenges in accessing and adhering 
to HIV treatment. Men’s ideal sense of  masculinity may 
be threatened by “disclosing their HIV status and seeking 
treatment in fear that they would be perceived as failing 
sons, husbands or breadwinners….”63 A study of  men in 
Uganda found that adherence challenged gender norms of  
masculinity, with men reporting that nurses scolded them: 
“It involves being shouted upon like a child, don’t you see, no respect 
at all.”64 Being physically strong, capable of  hard work and 
having children were also seen as signs of  masculine identity, 
which were threatened by being labeled HIV-positive. A 
study from South Africa found that men’s adherence was 
challenged by employment, with problems getting time away 
from work for clinic visits or loss of  income due to waiting 
in clinic lines.65
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Treatment may be undertaken by some men to regain health 
and self-worth with the ability to work and provide for their 
families as a sign of  their masculinity.66 In one South African 
study, when men were not yet on ART but diagnosed with 
HIV, family members withdrew support and care, as family 
members feared acquiring HIV. Once on ART and feeling 
physically well, men felt prepared to withstand potential 
rejection as well as confident to look for a girlfriend if  a 
partner rejected them for their positive serostatus.67 
Support groups and counseling for men may also be 
beneficial and men do request them.68 Focus group 
discussions in South Africa with men living with HIV 
on treatment who had disclosed to their partners found 
that they wanted to access male-only support groups with 
guarantees that their HIV status would not be disclosed 
outside of  the support group setting. Despite the fact that 
support groups were available four times per week, men did 
not know of  these support groups,69 which met at clinics 
where they collect their medication. In Uganda, men who 
were recipients of  financial support, such as expenses for 
children’s education or given livelihood options, such as 
goats, were more adherent than men without this support.70
Stigma and Gender Norms Can Make Efforts 
to Encourage Retention and Reduce HIV 
Transmission Difficult 
Non-judgmental, non-stigmatizing interventions both 
within the health sector and outside the health sector, such 
as transforming gender norms, reducing violence against 
women, revising laws that criminalize non-disclosure of  
HIV, to name a few,71 need to be implemented in order to 
support safer sexual behavior once someone knows his or 
her positive serostatus. 
Some serodiscordant couples identify fear of  transmission 
as a primary concern in their relationships or fear the impact 
that disclosure will have on the HIV-negative partner.72 A 
study in South Africa found that among 413 men living 
with HIV and 641 women living with HIV, stigma and 
discrimination was associated with non-disclosure and that 
non-disclosure was associated with HIV transmission risk 
behaviors.73
“Persistent rates of  nondisclosure by those diagnosed with 
HIV raise difficult ethical, public health and human rights 
questions about how to protect the medical confidentiality, 
health and well-being of  people living with HIV on the 
one hand, and how to protect partners and children from 
HIV transmission on the other.”74 Criminalization of  
transmission and nondisclosure undermines rights while 
serving little public health benefit, but gender issues are key 
to HIV disclosure.75 Because women are tested for HIV 
at much higher rates than men, any approach that blames 
women living with HIV for not disclosing their status will 
disproportionately burden women. Where male partners 
have been unwilling to get tested for HIV, some women 
living with HIV did not feel an obligation to disclose their 
positive serostatus.76 Women “reflected upon the fact that 
men seemed unwilling to test but preferred to blame their 
female partners.”77 In some cases, women are significantly 
less likely to know their partner’s status than men.78 And one 
study of  women living with HIV in South Africa found that 
consistent condom use was not correlated with disclosure 
to either HIV-negative or HIV-positive male partners.79 
For women living with HIV, “it is ultimately the decision 
of  the man to either use a male condom or not,”80 with 
gender norms on sexuality key to male use of  condoms. 
Some evaluated interventions exist regarding women’s 
use of  female condoms in the absence of  male condom 
use. However, “ …limited access to female condoms and 
substantially higher costs have limited uptake and use of  
female condoms,”81 thus limiting an opportunity to reduce 
HIV infection through a woman-initiated prevention 
method.
Transgender people can face a double stigma for their 
gender as well as for their positive serostatus, making 
accessing needed health and HIV services, which usually 
operate on strict male/female gender identities, extremely 
difficult. They are often overlooked in HIV treatment 
programming.
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Fear of Disclosure Impacts ART Retention and 
Transmission Reduction Efforts
Disclosure is not a one-time event but a process calling for 
careful consideration as to whom to disclose and when. A 
study in Zimbabwe of  200 women living with HIV on ART 
found that 96.5% disclosed to at least one person, most 
frequently their sister.82 Both women and men need to learn 
how to negotiate safe sex prior to disclosure, knowing when 
to disclose and how to disclose. Women in one study noted 
that once they disclosed, no man had stayed with them.83 In 
another study in Uganda, “the need to provide for children 
was a particularly strong motivation for women to avoid 
disclosure,”84 as men abandoned or abused partners who 
disclosed or requested condom use. One cross-sectional 
survey in Cameroon found that women living with HIV who 
were not financially dependent on their male partners were 
much more likely to have used condoms,85 suggesting the 
importance of  the enabling environment.
A study in South Africa found that for men, disclosure 
undermined their sense of  masculinity as health-seeking 
would portray them as weak and dependent, as well as 
subject to control by health care providers, noting that “men 
believed that ‘real men’ deal with personal problems on their 
own, instead of  asking help from other people.”86 However, 
once on ART, men’s health and appearance improved and 
they felt publicly able to share their HIV-positive serostatus, 
which in turn won them support, approval and admiration, 
becoming role models for breaking the secrecy and stigma 
surrounding HIV.87 Other studies found that men were 
particularly critical of  serodiscordant couple interventions, 
as couples counseling puts “the man on trial.” As one man 
put it: “It is as if  you are before a court, as you know women can get 
authority over the man when other people are there...So your wife may 
ask you how the disease came about. So you have to reveal the extra 
affairs….”88 Providing sex-segregated counseling may be 
more effective.89 
Priority Actions for Programming and Policy
 ■ Provide information and support
 — Within all treatment programs, counsel both men 
and women on their options if  they want to be-
come pregnant/have a child or avert unintended 
pregnancies.
 — Create sex-segregated ART support groups, sim-
ilar to the mothers2mothers model for pregnant 
women, for all who are living with HIV.
 — Strengthen training for counselors and other 
healthcare workers providing guidance on safe 
disclosure for both men and women (separate 
guidance for each, address gender issues for 
each).
 — Provide services that are user-friendly such as 
with on-site childcare or at times or locations that 
are women- men- and family-friendly.
 ■ Address legal barriers
 — Create or strengthen programs for the judicial 
sector to ensure ART is available within jails, 
prisons, etc. and that those living with HIV taken 
into custody can adhere to ART. (This is particu-
larly important for sex workers).
 — Decriminalize HIV transmission, which can be 
particularly harmful to women and may criminal-
ize vertical transmission during pregnancy.
 ■ Analyze gender dynamics
 — Review and design programs to ensure that they 
are based upon a gender analysis and address 
harmful gender norms and gender-based vio-
lence and are evaluated to better elucidate how 
a gender-sensitive approach affects treatment 
adherence and retention. 
Questions for Implementation Science
 ■ How can peer support be effectively provided for 
men and how does it differ from a peer support 
model for women?
Viral Suppression
ART adherence is critical to achieving viral suppression. 
Additional factors such as drug resistance, drug interactions 
and biological differences may also be subject to gender-
related challenges in achieving viral suppression.
Women may be at greater risk for viral drug resistance or 
transmitting drug resistant strains due to the temporary use 
of  antiretrovirals to reduce vertical transmission. Further 
evaluation is needed to understand these risks. While it is 
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clear that those who go on ARV therapy for their own 
treatment needs should not interrupt treatment,90 treatment 
interruption for women who are on ART to prevent 
perinatal transmission rather than for their own health 
needs is the subject of  an ongoing clinical trial (PROMISE), 
with results expected in 2017. “The risk for maternal 
health of  stopping…maternal triple ARV prophylaxis 
after breastfeeding cessation is unknown”91 – especially if  
a woman living with HIV has multiple pregnancies. WHO 
recommendations for Option B+, i.e., lifelong treatment for 
pregnant women, may reduce stopping and re-starting ART 
which can carry increased risk for mortality and morbidity. 
Monitoring drug interactions can be increasingly complex in 
populations that may also be using drugs for co-infections, 
co-morbidities, or recreationally. Cross-hormonal treatment 
protocols for transgender women and men may affect HIV 
treatment success. While there are currently no documented 
drug interactions among these medications and ARVs, 
further research is needed.92 It is possible that ART may 
lead to hormonal fluctuations and metabolic abnormalities 
among transgender women taking hormonal medications 
and close monitoring is needed.93 
There May be Sex Differences in ART Efficacy
Access to treatment by sex has been disaggregated in a 
number of  studies. However, few studies have analyzed 
sex differences. Studies to date have not shown differences 
in virologic efficacy of  ART by sex,94 although a number 
have suggested that sex may influence the frequency, 
presentation, and severity of  selected ARV-related adverse 
events.95 One study found differences in virologic failure 
(i.e., ART fails to suppress and sustain viral load to less than 
200 copies/mL) by sex, with women having an advantage 
over men.96 Another study found that women were more 
likely to have viral suppression and better ART outcomes97 
while other research found that women were in better 
clinical condition than men.98 “Although data are limited, 
there is evidence that women may metabolize and respond 
to specific medications, including ARV drugs, differently 
than men.”99 In some studies, however, women experience 
more adverse drug reactions than men.100
d’Arminio Monforte et al., 2013 notes “[a]lthough published 
data suggest that there are no significant differences in ART 
efficacy between women and men, it must be emphasized 
that this is a conclusion drawn from a limited evidence 
base.”101 ARVs are administered at fixed dosages that do 
not take into account the different body weight, etc. of  each 
sex.102 A study in Tanzania in which 70% of  the 234 patients 
were women found that after one year of  standard ART, 
a higher proportion of  females had an undetectable viral 
load but with less of  a CD4 cell increase than men. Women 
started treatment at a less advanced disease stage but women 
lost their immunological advantage over men despite a better 
virological treatment response. In addition, men were better 
informed about the use of  ART.103 Other studies have found 
that men are disadvantaged in ART due to differences in 
body weight compared to dose.104
The potential role of  sex differences in HIV disease 
progression and treatment response is an understudied 
area of  inquiry,105 with women under-represented in clinical 
trials.106 A review of  forty randomized controlled trials for 
18 new drug applications for antiretroviral therapy submitted 
to the U.S. Food & Drug Administration (FDA) between 
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Box 3
Results to Watch for
A number of ongoing efforts are looking at gender 
dynamics in HIV treatment. Major initiatives with results to 
watch for include:
• Key Barriers to Women’s Access to Treatment: Making 
‘Fast-Track’ a Reality: This collaboration of UN Women, 
ATHENA Network, AVAC, and Salamander Trust is 
undertaking a global multi-stage review of the status 
of access to antiretroviral therapy for women living 
with HIV that includes a literature review, community 
dialogues and country case studies. Expected late 
2015.
• Supporting Operational AIDS Research (Project 
SOAR): Population Council and partners are 
determining whether a community mobilization 
intervention can effectively change gender norms 
at the community level, and whether reductions in 
harmful gender norms contribute to better health 
service utilization, in particular services along the HIV 
care and treatment continuum. Expected 2018.
• STRIVE Research Consortium: A six-year consortium 
investigating the social norms and inequalities that 
drive HIV, including: gender inequality and violence, 
poor livelihood options, alcohol and drinking norms 
and stigma and considerations. Ongoing projects 
are taking place in India, South Africa and Tanzania 
through 2018.
• Accelerating Children’s HIV/AIDS Treatment Initiative 
(ACT): U.S. President’s Emergency Plan for AIDS 
Relief (PEPFAR) and the Children’s Investment Fund 
Foundation (CIFF) launched this two-year initiative to 
double the number of children receiving ART across 
ten priority African countries. Expected 2016.
2000 and 2008 found that only 20% of  trial participants 
were women.107 Even when women are included, sex-
specific analysis of  the data is rarely undertaken.108 No 
studies have addressed the possible interactions between 
ART and sexual hormones in both men and women, 
including pre, peri or post-menopause.109 At a minimum, 
“research data should be disaggregated by sex to ensure 
opportunities for [sex- and] gender-based analysis….” 110 
Priority Actions for Implementation Science
 ■ Analyze gender and sex differences in clinical 
data
 — Enroll more women in clinical trials and conduct 
more gender analyses of  the data in order to 
identify potential sex differences in antiretroviral 
efficacy and in ART impact on cardiovascular 
and other noncommunicable diseases affecting 
those living with HIV. 
 — Carry out further research on the effect of  ART 
on hormonal medications and vice versa. 
Above All, ART Programming Must 
Include Respect for Human Rights
Expanding access to ART while considering equity and 
human rights is urgently needed.111 WHO’s 2013 guidelines 
note “human rights and ethical principles should guide…
national treatment policies to ensure that they are equitable 
and meet the specific needs of  all beneficiaries.”112 Requiring 
people living with HIV to disclose their serostatus to sexual 
partners and/or community members in order to receive 
treatment, care or support is a human rights violation. 
Similarly, coercing women to accept contraception in 
order to access treatment violates women’s rights to make 
their own fertility choices. While “treatment buddies” can 
be supportive, requiring a treatment buddy or medical 
companion to access ARV therapy may place undue burdens 
on women and their children: a study of  1,453 patients 
in Uganda on the impact of  requiring patients to disclose 
their HIV status and have a “treatment buddy” or “medical 
companion” to access ARV therapy found that 41% of  the 
women chose a child as their medical companion versus 
14% of  the men. Individuals with limited networks may 
delay enrolling in or may drop out of  care when treatment 
support “buddies” are required.113 
START is Just the Beginning: Moving 
Forward in Ensuring Gender-Equitable 
ART 
Given the myriad ways that gender norms impact 
antiretroviral treatment access and adherence, it is crucial 
that HIV treatment programming recognize and address 
gender issues in order to achieve the 90-90-90 goals which 
seek to increase the numbers of  people who know their 
status, enroll and sustain ART treatment and achieve viral 
suppression. If  gender dynamics are not addressed within 
treatment programming and policy, efforts to increase 
treatment coverage will be undermined. 
Now that the Strategic Timing of  Antiretroviral Treatment 
(START) study has shown substantially improved outcomes 
for early treatment initiation,114 Kavanaugh et al. argue 
that states’ “core minimum obligations now include 
access to early ART for both individual and collective 
benefit. Governments can now reasonably be expected 
to enable early viral suppression through human rights-
based interventions….”115 These efforts must take into 
consideration the issue of  autonomy that women living 
with HIV have consistently raised with respect to healthcare 
decision-making, including whether and when to start 
treatment. “Despite potential individual and public health 
benefits for women living with HIV, the decision to begin 
treatment for HIV is a deeply personal decision that reflects 
a variety of  private, contextual and structural factors.”116 
Although there is a growing understanding and 
documentation of  how gender impacts HIV treatment, 
there remain few evaluated interventions demonstrating 
what works to overcome these gender-related barriers. 
A number of  questions and concerns remain: how will 
access to ART be prioritized? How will treatment be 
financed? How can ART be equitably accessible? How will 
gender dynamics be addressed in ensuring access? Most 
importantly, how can ART availability and accessibility 
be partnered with informed consent about the risks and 
benefits of  treatment so that all people living with HIV may 
decide for themselves how best to stay healthy and live full, 
productive lives?
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